Supply Chain Considerations for Ensuring Quality

WRIGHTSTUDIO - STOCK.ADOBE.COM

Disruptions in the bio/pharmaceutical supply chain that impact capacity and capabilities result in longer lead times for drug products, according to Ari Ojinaka, production manager at Astrea Bioseparations. The past two years of the COVID-19 pandemic have highlighted the importance of a healthy supply chain. “Through the pandemic, we have witnessed a significant reduction in inter-country transportation of goods and services and in-country COVID-19 restriction impacting capacity and capabilities to manufacture,” says Ojinaka.

Pharmaceutical Technology spoke with Ojinaka as well as Steve Kirk, vice-president Global Procurement, Catalent; Vincent Colicchio, vice-president, Supply Chain and External Manufacturing, Dr. Reddy’s Laboratories; and Hamilton Lenox, senior vice president–Business Development & Operations at LGM Pharma about the impact of COVID-19 on the supply chain and what companies can do to ensure the quality of their products.

Read this article in Pharmaceutical Technology's March 2022 Quality and Regulatory Sourcebook eBook.

About the author

Susan Haigney is managing editor of Pharmaceutical Technology.

Article Details

Pharmaceutical Technology eBook: Quality and Regulatory Sourcebook, March 2022 Pages: 46-51

Citation

When referring to this article, please cite it as S. Haigney, “Supply Chain Considerations for Ensuring Quality," Pharmaceutical Technology's Quality and Regulatory Sourcebook eBook (March 2022).